Kerry Campbell

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records
Address833 Chestnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    F32AI008202     (CAMPBELL, KERRY S)Jan 31, 1991
    NIH
    STRUCTURE AND FUNCTION OF MIG-ASSOCIATED MOLECULES
    Role: Principal Investigator

    R01CA083859     (CAMPBELL, KERRY S)Dec 1, 1999 - Jan 31, 2016
    NIH
    Molecular Regulation of Inhibitory Killer Cell Ig-like Receptors
    Role: Principal Investigator

    R56CA100226     (CAMPBELL, KERRY S)Apr 1, 2003 - Jun 30, 2012
    NIH
    Mechanisms of NK Cell Activation by the KIR2DL4 Receptor
    Role: Principal Investigator

    R01CA100226     (CAMPBELL, KERRY S)Mar 1, 2004 - Jun 30, 2009
    NIH
    Mechanisms of NK Cell Activation by the KIR2DL4 Receptor
    Role: Principal Investigator

    R21AI083891     (CAMPBELL, KERRY S)Jun 5, 2009 - May 31, 2012
    NIH
    Characterization of Type-2 Cytokine-Producing NK Cells
    Role: Principal Investigator

    R01CA194263     (FANG, CAROLYN Y)Jan 1, 2016 - Dec 31, 2021
    NIH
    Understanding Psychosocial and Immunologic Responses in Indolent Lymphoproliferative Disorders
    Role: Co-Principal Investigator

    U01AI148117     (SYKULEV, YURI)Jan 1, 2020 - Dec 31, 2024
    NIH
    Role of immune receptor clustering in controlling efficacy of antibody-dependent Fc?RIIIa-mediated cytotoxicity by NK cells
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Vendramini-Costa DB, Francescone R, Franco-Barraza J, Luong T, Graves M, de Aquino AM, Steele N, Gardiner JC, Dos Santos SAA, Ogier C, Malloy E, Borghaei L, Martinez E, Zhigarev DI, Tan Y, Lee H, Zhou Y, Cai KQ, Klein-Szanto AJ, Wang H, Andrake M, Dunbrack RL, Campbell K, Cukierman E. Netrin G1 Ligand is a new stromal immunomodulator that promotes pancreatic cancer. bioRxiv. 2024 May 18. PMID: 38798370.
      Citations:    
    2. Wasserman JS, Fowle H, Hashmi R, Atar D, Patel K, Yarmahmoodi A, Macfarlane AW, Tan Y, Cukierman E, Gligorijevic B, Karami A, Whelan KA, Campbell KS, Gra?a X. Derivation of human primary prostate epithelial cell lines by differentially targeting the CDKN2A locus along with expression of hTERT. Res Sq. 2024 May 06. PMID: 38766032.
      Citations:    
    3. Murayama T, Nakayama J, Jiang X, Miyata K, Morris AD, Cai KQ, Prasad RM, Ma X, Efimov A, Belani N, Gerstein ER, Tan Y, Zhou Y, Kim W, Maruyama R, Campbell KS, Chen L, Yang Y, Balachandran S, Canadas I. Targeting DHX9 triggers tumor-intrinsic interferon response and replication stress in Small Cell Lung Cancer. Cancer Discov. 2024 Jan 08. PMID: 38189443.
      Citations:    
    4. Zibelman M, MacFarlane AW, Costello K, McGowan T, O'Neill J, Kokate R, Borghaei H, Denlinger CS, Dotan E, Geynisman DM, Jain A, Martin L, Obeid E, Devarajan K, Ruth K, Alpaugh RK, Dulaimi EA, Cukierman E, Einarson M, Campbell KS, Plimack ER. A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors. Nat Commun. 2023 Jul 27; 14(1):4513. PMID: 37500647.
      Citations:    
    5. Jang HJ, Hostetter G, MacFarlane AW, Madaj Z, Ross EA, Hinoue T, Kulchycki JR, Burgos RS, Tafseer M, Alpaugh RK, Schwebel CL, Kokate R, Geynisman DM, Zibelman MR, Ghatalia P, Nichols PW, Chung W, Madzo J, Hahn NM, Quinn DI, Issa JJ, Topper MJ, Baylin SB, Shen H, Campbell KS, Jones PA, Plimack ER. A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. Clin Cancer Res. 2023 Mar 16. PMID: 36928921.
      Citations:    
    6. Campbell KS. Murine Cytomegalovirus Encodes a Specific Cell Surface Marker That Can Trigger Attack by NK Cells. J Immunol. 2023 03 01; 210(5):519-520. PMID: 36881870.
      Citations:    
    7. Tricarico R, Madzo J, Scher G, Cohen M, Jelinek J, Maegawa S, Nagarathinam R, Scher C, Chang WC, Nicolas E, Slifker M, Zhou Y, Devarajan K, Cai KQ, Kwok T, Nakajima P, Xu J, Mancuso P, Doneddu V, Bagella L, Williams R, Balachandran S, Maskalenko N, Campbell K, Ma X, Ca?adas I, Viana J, Moreno V, Valle L, Grivennikov S, Peshkova I, Kurilenko N, Mazitova A, Koltsova E, Lee H, Walsh M, Duttweiler R, Whetstine JR, Yen TJ, Issa JP, Bellacosa A. TET1 and TDG suppress inflammatory response in intestinal tumorigenesis: implications for colorectal tumors with the CpG Island Methylator Phenotype. Gastroenterology. 2023 Feb 08. PMID: 36764492.
      Citations:    
    8. Richardson K, Keam SP, Zhu JJ, Meyran D, D'Souza C, Macdonald S, Campbell K, Robbins M, Bezman NA, Todd K, Quach H, Ritchie DS, Harrison SJ, Prince HM, Trapani JA, Jenkins MR, Beavis PA, Darcy PK, Neeson PJ. The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells. Haematologica. 2023 01 01; 108(1):83-97. PMID: 35770527.
      Citations:    
    9. Valentine H, Aiken W, Morrison B, Zhao Z, Fowle H, Wasserman JS, Thompson E, Chin W, Young M, Clarke S, Gibbs D, Harrison S, McLaughlin W, Kwok T, Jin F, Campbell KS, Horvath A, Thompson R, Lee NH, Zhou Y, Gra?a X, Ragin C, Badal S. Expanding the prostate cancer cell line repertoire with ACRJ-PC28, an AR-negative neuroendocrine cell line derived from an African-Caribbean patient. Cancer Res Commun. 2022 Nov; 2(11):1355-1371. PMID: 36643868.
      Citations:    
    10. Aghayev T, Mazitova AM, Fang JR, Peshkova IO, Rausch M, Hung M, White KF, Masia R, Titerina EK, Fatkhullina AR, Cousineau I, Turcotte S, Zhigarev D, Marchenko A, Khoziainova S, Makhov P, Tan YF, Kossenkov AV, Wiest DL, Stagg J, Wang XW, Campbell KS, Dzutsev AK, Trinchieri G, Hill JA, Grivennikov SI, Koltsova EK. IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma. Cancer Discov. 2022 08 05; 12(8):1960-1983. PMID: 35723626.
      Citations:    
    11. Zhigarev D, Varshavsky A, MacFarlane AW, Jayaguru P, Barreyro L, Khoreva M, Dulaimi E, Nejati R, Drenberg C, Campbell KS. Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology. Cancers (Basel). 2022 Jul 10; 14(14). PMID: 35884414.
      Citations:    
    12. Iraqi M, Edri A, Greenshpan Y, Goldstein O, Ofir N, Bolel P, Abu Ahmad M, Zektser M, Campbell KS, Rouvio O, Gazit R, Porgador A. Blocking the PCNA/NKp44 Checkpoint to Stimulate NK Cell Responses to Multiple Myeloma. Int J Mol Sci. 2022 Apr 25; 23(9). PMID: 35563109.
      Citations:    
    13. Maskalenko NA, Zhigarev D, Campbell KS. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat Rev Drug Discov. 2022 08; 21(8):559-577. PMID: 35314852.
      Citations:    
    14. Ford JW, Gonzalez-Cotto M, MacFarlane AW, Peri S, Howard OMZ, Subleski JJ, Ruth KJ, Haseebuddin M, Al-Saleem T, Yang Y, Rayman P, Rini B, Linehan WM, Finke J, Weiss JM, Campbell KS, McVicar DW. Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma. Front Oncol. 2021; 11:662723. PMID: 35223446.
      Citations:    
    15. Belnoue E, Leystra AA, Carboni S, Cooper HS, Macedo RT, Harvey KN, Colby KB, Campbell KS, Vanderveer LA, Clapper ML, Derouazi M. Novel Protein-Based Vaccine against Self-Antigen Reduces the Formation of Sporadic Colon Adenomas in Mice. Cancers (Basel). 2021 Feb 17; 13(4). PMID: 33671373.
      Citations:    
    16. Campbell KS. Mystery Checkpoint Revealed: KIR3DL3 Finally Found a Ligand in HHLA2. Cancer Immunol Res. 2021 02; 9(2):128. PMID: 33536266.
      Citations:    
    17. Pazina T, MacFarlane AW, Bernabei L, Dulaimi E, Kotcher R, Yam C, Bezman NA, Robbins MD, Ross EA, Campbell KS, Cohen AD. Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma. Cancers (Basel). 2021 Jan 10; 13(2). PMID: 33435153.
      Citations:    
    18. MacFarlane AW, Yeung HM, Alpaugh RK, Dulaimi E, Engstrom PF, Dasari A, Campbell KS, Vijayvergia N. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms. Cancer Immunol Immunother. 2021 Jul; 70(7):1893-1906. PMID: 33398390.
      Citations:    
    19. Fernandez SV, MacFarlane AW, Jillab M, Arisi MF, Yearley J, Annamalai L, Gong Y, Cai KQ, Alpaugh RK, Cristofanilli M, Campbell KS. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer. Breast Cancer Res. 2020 Dec 02; 22(1):134. PMID: 33267869.
      Citations:    
    20. Francescone R, Barbosa Vendramini-Costa D, Franco-Barraza J, Wagner J, Muir A, Lau AN, Gabitova L, Pazina T, Gupta S, Luong T, Rollins D, Malik R, Thapa RJ, Restifo D, Zhou Y, Cai KQ, Hensley HH, Tan Y, Kruger WD, Devarajan K, Balachandran S, Klein-Szanto AJ, Wang H, El-Deiry WS, Vander Heiden MG, Peri S, Campbell KS, Astsaturov I, Cukierman E. Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblast-Driven Nutritional Support and Immunosuppression. Cancer Discov. 2021 02; 11(2):446-479. PMID: 33127842.
      Citations:    
    21. Ralff MD, Jhaveri A, Ray JE, Zhou L, Lev A, Campbell KS, Dicker DT, Ross EA, El-Deiry WS. TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic. Oncotarget. 2020 Oct 20; 11(42):3753-3769. PMID: 33144917.
      Citations:    
    22. Zhou L, Huntington K, Zhang S, Carlsen L, So EY, Parker C, Sahin I, Safran H, Kamle S, Lee CM, Lee CG, Elias JA, Campbell KS, Naik MT, Atwood WJ, Youssef E, Pachter JA, Navaraj A, Seyhan AA, Liang O, El-Deiry WS. Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells. bioRxiv. 2020 Sep 02. PMID: 32793908.
      Citations:    
    23. Badal S, Campbell KS, Valentine H, Ragin C. The need for cell lines from diverse ethnic backgrounds for prostate cancer research. Nat Rev Urol. 2019 12; 16(12):691-692. PMID: 31520083.
      Citations:    
    24. Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney AY, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma. Cancer Immunol Res. 2019 10; 7(10):1633-1646. PMID: 31431433.
      Citations:    
    25. Kundu K, Ghosh S, Sarkar R, Edri A, Brusilovsky M, Gershoni-Yahalom O, Yossef R, Shemesh A, Soria JC, Lazar V, Joshua BZ, Campbell KS, Elkabets M, Porgador A. Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA. Cancer Immunol Res. 2019 07; 7(7):1120-1134. PMID: 31164357.
      Citations:    
    26. Barta SK, Zain J, MacFarlane AW, Smith SM, Ruan J, Fung HC, Tan CR, Yang Y, Alpaugh RK, Dulaimi E, Ross EA, Campbell KS, Khan N, Siddharta R, Fowler NH, Fisher RI, Oki Y. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):356-364.e3. PMID: 31029646.
      Citations:    
    27. Cheng H, Schwell V, Curtis BR, Fazlieva R, Roder H, Campbell KS. Conformational Changes in the Cytoplasmic Region of KIR3DL1 upon Interaction with SHP-2. Structure. 2019 04 02; 27(4):639-650.e2. PMID: 30773397.
      Citations:    
    28. Tomalka AG, Resto-Garay I, Campbell KS, Popkin DL. In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol. 2018; 9:2552. PMID: 30455699.
      Citations:    
    29. Campbell KS, Cohen AD, Pazina T. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front Immunol. 2018; 9:2551. PMID: 30455698.
      Citations:    
    30. Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest. 2018 06 01; 128(6):2325-2338. PMID: 29533922.
      Citations:    
    31. Shemesh A, Brusilovsky M, Kundu K, Ottolenghi A, Campbell KS, Porgador A. Splice variants of human natural cytotoxicity receptors: novel innate immune checkpoints. Cancer Immunol Immunother. 2018 Dec; 67(12):1871-1883. PMID: 29264698.
      Citations:    
    32. Finnberg NK, Gokare P, Lev A, Grivennikov SI, MacFarlane AW, Campbell KS, Winters RM, Kaputa K, Farma JM, Abbas AE, Grasso L, Nicolaides NC, El-Deiry WS. Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures. Oncotarget. 2017 Sep 15; 8(40):66747-66757. PMID: 28977993.
      Citations:    
    33. Pazina T, James AM, MacFarlane AW, Bezman NA, Henning KA, Bee C, Graziano RF, Robbins MD, Cohen AD, Campbell KS. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. Oncoimmunology. 2017; 6(9):e1339853. PMID: 28932638.
      Citations:    
    34. MacFarlane AW, Jillab M, Smith MR, Alpaugh RK, Cole ME, Litwin S, Millenson MM, Al-Saleem T, Cohen AD, Campbell KS. NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. Oncoimmunology. 2017; 6(7):e1330235. PMID: 28811973.
      Citations:    
    35. Pazina T, Shemesh A, Brusilovsky M, Porgador A, Campbell KS. Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions with Diverse Ligands and Alterations in Splice Variant Expression. Front Immunol. 2017; 8:369. PMID: 28424697.
      Citations:    
    36. Peri S, Caretti E, Tricarico R, Devarajan K, Cheung M, Sementino E, Menges CW, Nicolas E, Vanderveer LA, Howard S, Conrad P, Crowell JA, Campbell KS, Ross EA, Godwin AK, Yeung AT, Clapper ML, Uzzo RG, Henske EP, Ricketts CJ, Vocke CD, Linehan WM, Testa JR, Bellacosa A, Kopelovich L, Knudson AG. Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation. Oncotarget. 2017 Mar 14; 8(11):17628-17642. PMID: 27682873.
      Citations:    
    37. Shemer-Avni Y, Kundu K, Shemesh A, Brusilovsky M, Yossef R, Meshesha M, Solomon-Alemayehu S, Levin S, Gershoni-Yahalom O, Campbell KS, Porgador A. Expression of NKp46 Splice Variants in Nasal Lavage Following Respiratory Viral Infection: Domain 1-Negative Isoforms Predominate and Manifest Higher Activity. Front Immunol. 2017; 8:161. PMID: 28261217.
      Citations:    
    38. Bobrov E, Skobeleva N, Restifo D, Beglyarova N, Cai KQ, Handorf E, Campbell K, Proia DA, Khazak V, Golemis EA, Astsaturov I. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. Oncotarget. 2017 Jan 17; 8(3):4399-4409. PMID: 27779106.
      Citations:    
    39. Jochems C, Hodge JW, Fantini M, Fujii R, Morillon YM, Greiner JW, Padget MR, Tritsch SR, Tsang KY, Campbell KS, Klingemann H, Boissel L, Rabizadeh S, Soon-Shiong P, Schlom J. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget. 2016 Dec 27; 7(52):86359-86373. PMID: 27861156.
      Citations:    
    40. Shemesh A, Kugel A, Steiner N, Yezersky M, Tirosh D, Edri A, Teltsh O, Rosental B, Sheiner E, Rubin E, Campbell KS, Porgador A. NKp44 and NKp30 splice variant profiles in decidua and tumor tissues: a comparative viewpoint. Oncotarget. 2016 Oct 25; 7(43):70912-70923. PMID: 27765926.
      Citations:    
    41. Shemesh A, Brusilovsky M, Hadad U, Teltsh O, Edri A, Rubin E, Campbell KS, Rosental B, Porgador A. Survival in acute myeloid leukemia is associated with NKp44 splice variants. Oncotarget. 2016 May 31; 7(22):32933-45. PMID: 27102296.
      Citations:    
    42. Campbell KS. Suppressing the killer instinct. Sci Signal. 2016 05 24; 9(429):fs8. PMID: 27221707.
      Citations:    
    43. Ge MQ, Kokalari B, Flayer CH, Killingbeck SS, Redai IG, MacFarlane AW, Hwang JW, Kolupoti A, Kemeny DM, Campbell KS, Haczku A. Correction: Cutting Edge: Role of NK Cells and Surfactant Protein D in Dendritic Cell Lymph Node Homing: Effects of Ozone Exposure. J Immunol. 2016 Apr 01; 196(7):3212. PMID: 26994305.
      Citations:    
    44. Davis ZB, Cogswell A, Scott H, Mertsching A, Boucau J, Wambua D, Le Gall S, Planelles V, Campbell KS, Barker E. A Conserved HIV-1-Derived Peptide Presented by HLA-E Renders Infected T-cells Highly Susceptible to Attack by NKG2A/CD94-Bearing Natural Killer Cells. PLoS Pathog. 2016 Feb; 12(2):e1005421. PMID: 26828202.
      Citations:    
    45. Kaileh M, Vazquez E, MacFarlane AW, Campbell K, Kurosaki T, Siebenlist U, Sen R. mTOR-Dependent and Independent Survival Signaling by PI3K in B Lymphocytes. PLoS One. 2016; 11(1):e0146955. PMID: 26785352.
      Citations:    
    46. Ge MQ, Kokalari B, Flayer CH, Killingbeck SS, Redai IG, MacFarlane AW, Hwang JW, Kolupoti A, Kemeny MD, Campbell KS, Haczku A. Cutting Edge: Role of NK Cells and Surfactant Protein D in Dendritic Cell Lymph Node Homing: Effects of Ozone Exposure. J Immunol. 2016 Jan 15; 196(2):553-7. PMID: 26673133.
      Citations:    
    47. Frishman-Levy L, Shemesh A, Bar-Sinai A, Ma C, Ni Z, Frenkel S, Muench V, Bruckmueller H, Vokuhl C, Debatin KM, Eckert C, Stanulla M, Schrappe M, Campbell KS, Loewenthal R, Schewe DM, Hochman J, Meyer LH, Kaufman D, Cario G, Porgador A, Izraeli S. Central nervous system acute lymphoblastic leukemia: role of natural killer cells. Blood. 2015 May 28; 125(22):3420-31. PMID: 25896649.
      Citations:    
    48. Steblyanko M, Anikeeva N, Campbell KS, Keen JH, Sykulev Y. Integrins Influence the Size and Dynamics of Signaling Microclusters in a Pyk2-dependent Manner. J Biol Chem. 2015 May 8; 290(19):11833-42. PMID: 25778396.
      Citations:    
    49. Brusilovsky M, Radinsky O, Cohen L, Yossef R, Shemesh A, Braiman A, Mandelboim O, Campbell KS, Porgador A. Regulation of natural cytotoxicity receptors by heparan sulfate proteoglycans in -cis: A lesson from NKp44. Eur J Immunol. 2015 Apr; 45(4):1180-91. PMID: 25546090.
      Citations:    
    50. Purdy AK, Alvarez Arias DA, Oshinsky J, James AM, Serebriiskii I, Campbell KS. The ap-2 clathrin adaptor mediates endocytosis of an inhibitory killer cell Ig-like receptor in human NK cells. J Immunol. 2014 Nov 01; 193(9):4675-83. PMID: 25238755.
      Citations:    
    51. Brusilovsky M, Radinsky O, Yossef R, Campbell KS, Porgador A. Carbohydrate-mediated modulation of NK cell receptor function: structural and functional influences of heparan sulfate moieties expressed on NK cell surface. Front Oncol. 2014; 4:185. PMID: 25077071.
      Citations:    
    52. Anikeeva N, Steblyanko M, Fayngerts S, Kopylova N, Marshall DJ, Powers GD, Sato T, Campbell KS, Sykulev Y. Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity. Eur J Immunol. 2014 Aug; 44(8):2331-9. PMID: 24810893.
      Citations:    
    53. Afanador L, Roltsch EA, Holcomb L, Campbell KS, Keeling DA, Zhang Y, Zimmer DB. The Ca2+ sensor S100A1 modulates neuroinflammation, histopathology and Akt activity in the PSAPP Alzheimer's disease mouse model. Cell Calcium. 2014 Aug; 56(2):68-80. PMID: 24931125.
      Citations:    
    54. Mentlik James A, Cohen AD, Campbell KS. Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol. 2013 Dec 23; 4:481. PMID: 24391651.
      Citations:    
    55. MacFarlane AW, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, Dulaimi E, Al-Saleem T, Campbell KS. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res. 2014 Apr; 2(4):320-31. PMID: 24764579.
      Citations:    
    56. Brusilovsky M, Cordoba M, Rosental B, Hershkovitz O, Andrake MD, Pecherskaya A, Einarson MB, Zhou Y, Braiman A, Campbell KS, Porgador A. Genome-wide siRNA screen reveals a new cellular partner of NK cell receptor KIR2DL4: heparan sulfate directly modulates KIR2DL4-mediated responses. J Immunol. 2013 Nov 15; 191(10):5256-67. PMID: 24127555.
      Citations:    
    57. Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. 2013 Sep; 132(3):536-544. PMID: 23906377.
      Citations:    
    58. Lucas CR, Cordero-Nieves HM, Erbe RS, McAlees JW, Bhatia S, Hodes RJ, Campbell KS, Sanders VM. Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes. J Immunol. 2013 Jan 15; 190(2):723-36. PMID: 23241883.
      Citations:    
    59. Grier JT, Forbes LR, Monaco-Shawver L, Oshinsky J, Atkinson TP, Moody C, Pandey R, Campbell KS, Orange JS. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest. 2012 Oct; 122(10):3769-80. PMID: 23006327.
      Citations:    
    60. Rosental B, Hadad U, Brusilovsky M, Campbell KS, Porgador A. A novel mechanism for cancer cells to evade immune attack by NK cells: The interaction between NKp44 and proliferating cell nuclear antigen. Oncoimmunology. 2012 Jul 01; 1(4):572-574. PMID: 22754791.
      Citations:    
    61. Ni M, MacFarlane AW, Toft M, Lowell CA, Campbell KS, Hamerman JA. B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K. Proc Natl Acad Sci U S A. 2012 Jan 03; 109(1):267-72. PMID: 22187458.
      Citations:    
    62. Rosental B, Brusilovsky M, Hadad U, Oz D, Appel MY, Afergan F, Yossef R, Rosenberg LA, Aharoni A, Cerwenka A, Campbell KS, Braiman A, Porgador A. Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol. 2011 Dec 01; 187(11):5693-702. PMID: 22021614.
      Citations:    
    63. Miah SM, Purdy AK, Rodin NB, MacFarlane AW, Oshinsky J, Alvarez-Arias DA, Campbell KS. Ubiquitylation of an internalized killer cell Ig-like receptor by Triad3A disrupts sustained NF-?B signaling. J Immunol. 2011 Mar 01; 186(5):2959-69. PMID: 21270397.
      Citations:    
    64. Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology. 2011 Mar; 132(3):315-25. PMID: 21214544.
      Citations:    
    65. Purdy AK, Campbell KS. [Natural killer cells and cancer. Regulation by the killer cell Ig-like receptors (KIR)]. Zhongguo Fei Ai Za Zhi. 2010 Jul; 13(7):731-6. PMID: 21644387.
      Citations:    
    66. Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, Bove B, Slater C, Zhou Y, Daly M, Howard S, Campbell KS, Nicolas E, Yeung AT, Clapper ML, Crowell JA, Lynch HT, Ross E, Kopelovich L, Knudson AG. Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila). 2010 Jan; 3(1):48-61. PMID: 20051372.
      Citations:    
    67. MacFarlane AW, Oesterling JF, Campbell KS. Measuring intracellular calcium signaling in murine NK cells by flow cytometry. Methods Mol Biol. 2010; 612:149-57. PMID: 20033639.
      Citations:    
    68. Miah SM, Campbell KS. Expression of cDNAs in human Natural Killer cell lines by retroviral transduction. Methods Mol Biol. 2010; 612:199-208. PMID: 20033642.
      Citations:    
    69. Purdy AK, Campbell KS. Introduction of shRNAs into human NK-like cell lines with retrovirus. Methods Mol Biol. 2010; 612:223-31. PMID: 20033644.
      Citations:    
    70. Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther. 2009 Dec; 8(23):2211-20. PMID: 19923897.
      Citations:    
    71. Purdy AK, Campbell KS. SHP-2 expression negatively regulates NK cell function. J Immunol. 2009 Dec 01; 183(11):7234-43. PMID: 19915046.
      Citations:    
    72. Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur J Pharmacol. 2009 Dec 25; 625(1-3):41-54. PMID: 19837059.
      Citations:    
    73. Hershkovitz O, Rosental B, Rosenberg LA, Navarro-Sanchez ME, Jivov S, Zilka A, Gershoni-Yahalom O, Brient-Litzler E, Bedouelle H, Ho JW, Campbell KS, Rager-Zisman B, Despres P, Porgador A. NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. J Immunol. 2009 Aug 15; 183(4):2610-21. PMID: 19635919.
      Citations:    
    74. Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol. 2008 May 01; 180(9):6392-401. PMID: 18424763.
      Citations:    
    75. MacFarlane AW, Yamazaki T, Fang M, Sigal LJ, Kurosaki T, Campbell KS. Enhanced NK-cell development and function in BCAP-deficient mice. Blood. 2008 Jul 01; 112(1):131-40. PMID: 18337558; PMCID: PMC2435684.
      Citations:    
    76. Miah SM, Hughes TL, Campbell KS. KIR2DL4 differentially signals downstream functions in human NK cells through distinct structural modules. J Immunol. 2008 Mar 01; 180(5):2922-32. PMID: 18292514.
      Citations:    
    77. Alvarez-Arias DA, Campbell KS. Protein kinase C regulates expression and function of inhibitory killer cell Ig-like receptors in NK cells. J Immunol. 2007 Oct 15; 179(8):5281-90. PMID: 17911614.
      Citations:    
    78. Chen Y, Perussia B, Campbell KS. Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor. J Immunol. 2007 Sep 01; 179(5):2766-73. PMID: 17709490.
      Citations:    
    79. Hershkovitz O, Jivov S, Bloushtain N, Zilka A, Landau G, Bar-Ilan A, Lichtenstein RG, Campbell KS, van Kuppevelt TH, Porgador A. Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44. Biochemistry. 2007 Jun 26; 46(25):7426-36. PMID: 17536787.
      Citations:    
    80. Brando C, Mukhopadhyay S, Kovacs E, Medina R, Patel P, Catina TL, Campbell KS, Santoli D. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104. J Leukoc Biol. 2005 Aug; 78(2):359-71. PMID: 15937142.
      Citations:    
    81. Kikuchi-Maki A, Catina TL, Campbell KS. Cutting edge: KIR2DL4 transduces signals into human NK cells through association with the Fc receptor gamma protein. J Immunol. 2005 Apr 01; 174(7):3859-63. PMID: 15778339.
      Citations:    
    82. Stoyanova R, Clapper ML, Bellacosa A, Henske EP, Testa JR, Ross EA, Yeung AT, Nicolas E, Tsichlis N, Li YS, Linehan WM, Howard S, Campbell KS, Godwin AK, Boman BM, Crowell JA, Kopelovich L, Knudson AG. Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther. 2004 Dec; 3(12):1313-21. PMID: 15662135.
      Citations:    
    83. Yusa S, Catina TL, Campbell KS. KIR2DL5 can inhibit human NK cell activation via recruitment of Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2). J Immunol. 2004 Jun 15; 172(12):7385-92. PMID: 15187115.
      Citations:    
    84. Campbell KS, Yusa S, Kikuchi-Maki A, Catina TL. NKp44 triggers NK cell activation through DAP12 association that is not influenced by a putative cytoplasmic inhibitory sequence. J Immunol. 2004 Jan 15; 172(2):899-906. PMID: 14707061.
      Citations:    
    85. Kikuchi-Maki A, Yusa S, Catina TL, Campbell KS. KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-gamma production. J Immunol. 2003 Oct 01; 171(7):3415-25. PMID: 14500636.
      Citations:    
    86. Kloeker S, Reed R, McConnell JL, Chang D, Tran K, Westphal RS, Law BK, Colbran RJ, Kamoun M, Campbell KS, Wadzinski BE. Parallel purification of three catalytic subunits of the protein serine/threonine phosphatase 2A family (PP2A(C), PP4(C), and PP6(C)) and analysis of the interaction of PP2A(C) with alpha4 protein. Protein Expr Purif. 2003 Sep; 31(1):19-33. PMID: 12963337.
      Citations:    
    87. Yusa S, Campbell KS. Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2) can play a direct role in the inhibitory function of killer cell Ig-like receptors in human NK cells. J Immunol. 2003 May 01; 170(9):4539-47. PMID: 12707331.
      Citations:    
    88. Yusa S, Catina TL, Campbell KS. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells. J Immunol. 2002 May 15; 168(10):5047-57. PMID: 11994457.
      Citations:    
    Campbell's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (427)
    Explore
    _
    Co-Authors (9)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _